Real-world baseline characteristics and diagnostic path of Polish patients with ALK-positive NSCLC eligible for brigatinib treatment: Interim results from the ENTIRETY study.

Authors: Katarzyna Magdalena Stencel, Grzegorz Czyżewicz, Tomasz Jankowski, Aleksandra Stryjkowska-Góra, Katarzyna Zajda, Joanna Luboch Kowal, Brygida Brudny-Borowska, Pawel Sliwinski, Emil Wojda, Eliza Majewska, Rodryg Ramlau, Dariusz M. Kowalski

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20640

Source: Full article

---

Abstract

e20640